2021-08-24| Special

The 6 Companies Leading the Resurgence in RNA Editing R&D

by Tyler Chen
Share To
Despite the transcending advance of CRISPR gene editing, interest in RNA editing is slowly catching on. A handful of companies are now launching projects banking on innovative technologies to draw investor attention.

Current research endeavors focus on the applications of the human RNA editing enzymes called ADARs (adenosine deaminase act on double-stranded RNA). ADAR enlists the help of guide RNA (gRNA), which shuttles it to a target location to carry out precise and efficient editing.

Here is our list of six companies and their research indications, target areas, and fundraising power to bring you up to speed on the frontrunners of a growing industry. GeneOnline lists emerging RNA editing companies that are set to make a mark in 2021

GO Prime with only $1.49 now

10x Genomics Eyes Regional Opportunities in Asia-Pacific, Launches First Overseas Manufacturing Hub
Shaping the Future of the Beauty Industry: Can Skin Microbiome Products Succeed Cosmetics?
Sanofi, Regeneron’s Dupixent Shines in Phase 3 Trial for Prurigo Nodularis
ReCode Therapeutics Raises $80 Million in Series B to Advance Gene Therapy & LNP Delivery Platform
Intellia’s CRISPR Drug Claims FDA Orphan Drug Designation to Treat ATTR Amyloidosis
Sio Gene Therapies Touts Positive Safety and Biomarker Data for GM1 Gangliosidosis Candidate
Daiichi Sankyo to Launch mRNA Covid-19 Vaccine in 2022, Shionogi Presents Clinical Results of Covid-19 Oral Drug
Scroll to Top

Create an account with us now to say goodbye to all the pop-ups!